Prosecution Insights
Last updated: November 11, 2026
Application No. 18/849,801

USE OF FOLLISTATIN-LIKE 1 (FSTL1) IN CARDIOMETABOLIC HEART FAILURE

Non-Final OA §112
Filed
Sep 23, 2024
Priority
Mar 25, 2022 — provisional 63/324,018 +2 more
Examiner
BUNNER, BRIDGET E
Art Unit
1647
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Regencor Inc.
OA Round
1 (Non-Final)
65%
Grant Probability
Moderate
1-2
OA Rounds
8m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allowance Rate
547 granted / 846 resolved
+4.7% vs TC avg
Strong +20% interview lift
Without
With
+19.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
38 currently pending
Career history
890
Total Applications
across all art units

Statute-Specific Performance

§101
6.4%
-33.6% vs TC avg
§103
15.5%
-24.5% vs TC avg
§102
18.7%
-21.3% vs TC avg
§112
38.0%
-2.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 846 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Application, Amendments and/or Claims The amendment of 30 April 2025 has been entered in full. Claims 5, 6, 9, 23, 25, 35, and 36 are amended. Claims 7, 8, 10-22, and 26-34 are cancelled. Claims 1-6, 9, 23, 25, and 35-37 are under consideration in the instant application. Information Disclosure Statement The information disclosure statement (IDS) submitted on 27 May 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Nucleotide and/or Amino Acid Sequence Disclosures Summary of Requirements for Patent Applications Filed On Or After July 1, 2022, That Have Sequence Disclosures 37 CFR 1.831(a) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.831(b) must contain a “Sequence Listing XML”, as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.831-1.835. This “Sequence Listing XML” part of the disclosure may be submitted: 1. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter “Legal Framework”) in XML format, together with an incorporation by reference statement of the material in the XML file in a separate paragraph of the specification (an incorporation by reference paragraph) as required by 37 CFR 1.835(a)(2) or 1.835(b)(2) identifying: a. the name of the XML file b. the date of creation; and c. the size of the XML file in bytes; or 2. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation by reference statement of the material in the XML format according to 37 CFR 1.52(e)(8) and 37 CFR 1.835(a)(2) or 1.835(b)(2) in a separate paragraph of the specification identifying: a. the name of the XML file; b. the date of creation; and c. the size of the XML file in bytes. 1. SPECIFIC DEFICIENCIES AND THE REQUIRED RESPONSE TO THIS NOTICE ARE AS FOLLOWS: 1a. Specific deficiency - The incorporation by reference paragraph required by 37 CFR 1.834(c)(1), 1.835(a)(2), or 1.835(b)(2) is missing, defective or incomplete. Specifically, the incorporation by reference paragraph does not identify the size of the sequence listing file in bytes. Rather, the paragraph indicates that the file is 7.4 KB (kilobytes). 1b. Required response - Applicant must: • Provide a substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125 inserting the required incorporation by reference paragraph, consisting of: • A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version); • A copy of the amended specification without markings (clean version); and • A statement that the substitute specification contains no new matter. Claim Objections 2. Claim 23 is objected to because of the following informalities: 2a. In claim 23, subparts (e) and (f) are identical and one should be deleted. 2b. In claim 23, at the end of subpart (j), the word “or” is missing and should be inserted. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 3. Claims 1-2, 4-6, 9, 23, 25, and 35-37 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. 3a. Claims 1-2, 4-6, 9, 23, 25, and 35-37 are rejected as being indefinite because it is not clear in the preamble of independent claims 1 and 2 what the distinction is between “aiding cardiometabolic heart failure treatment” and “treating cardiometabolic heart failure”. The specification does not provide specific definitions for “aiding” or “treating”, so are the phrases “aiding cardiometabolic heart failure treatment” and “treating cardiometabolic heart failure” duplicative? If they are intended to be different, how so? One of ordinary skill in the art would not be reasonably apprised of the scope of the invention. 3b. Claims 1-2, 4-5, 23, 25, and 35-37 are rejected as being indefinite because it is not clear in independent claims 1 and 2 what therapeutic effect must be achieved by the contacting step recited in line 2. 3c. Claims 36 and 37 are rejected as being indefinite because claim 36 recites, “the method further comprising an inhibitor of FSTL1 glycosylation”. It is not clear how the claimed method further comprises an inhibitor. Is the inhibitor administered? Does the inhibitor contact tissue? Is it formulated into a composition with the FSTL1 polypeptide? Claim 36 seems to be missing a word or phrase to enable one skilled in the art to be reasonably apprised of the scope of the claim. Conclusion Claims 1-2, 4-6, 9, 23, 25, and 35-37 are rejected. Claim 3 is allowable. The art made of record and not relied upon is considered pertinent to applicant's disclosure: ** Ruiz-Lozano et al. (WO 2016/164840; US 2018/0092980; U.S. Patent 10,682,416 (cited on the IDS of 27 May 2026)) (teach methods for repairing cardiac tissue by hypoglycosylated FSTL1; do not teach cardiometabolic heart failure) **Yang et al. J Cardiovascular Dev Disease 13: 291, 2026 (review cardiometabolic heart failure; teach that CM-HFpEF is phenotypically and mechanistically distinct from non-CM-HFpEF (page 6; Figure 3) (page 2, 1st full paragraph)) El-Armouche et al. Circ Heart Fail 4: 621-627, 2011 (teach elevated serum FSTL1 levels in humans with chronic, stable HFrEF (heart failure with reduced ejection fraction; systolic); teach that elevated levels FSTL1 levels are significantly associated with LV mass and circulating BNP levels, suggesting a pathogenic role for FSTL1 cardiac remodeling and LVH (abstract; page 624)) Magadum et al. Mol Ther Nucl Acids 13: 133-143, 2018 (cited on the IDS of 27 May 2026) (teach FSTL1 levels decline in epicardium but increase in myocardium after myocardial infarction (page 134, column 1, 2nd full paragraph); teach glycosylation sites in FSTL1 (page 134, column 2, last paragraph); also disclose that the mutation of a single glycosylation site increases proliferation of rat and mouse cardiomyocytes in vitro and after myocardial infarction in vivo; do not teach cardiometabolic heart failure) Chen et al. Mech Dev 145(Suppl): S27, 2017 (cited on the IDS of 27 May 2026) (teach FSTL1 attenuates hyperglycemia-induced endothelial dysfunction) Mattiotti et al. Cell Mol Life Sci 75: 2339-2354, 2018 (review of FSTL1 and its role in cardiovascular disease, including heart failure, myocardial infarction, cardiac hypertrophy; teach that the glycosylation state of FSTL1 plays a role in biological function (abstract; pages 2339-2342; page 2341, bottom of column 2); do not teach FSTL1 treats cardiometabolic heart failure or repairs cardiac tissue following cardiometabolic heart failure) Ruiz-Lozano et al. bioRxiv preprint doi: https://doi.org/10.1101/2025.10.15.679868 (15 October 2025) (common inventor with instant application; teach several of the findings of the examples of the instant application) Tanaka et al. J Am Coll Cardiol Basic Trans Science 1(4): 207-221, 2016 (teach the administration of recombinant FSTL1 reduces cardiac hypertrophy in mice with hypertension-induced heart failure with preserved ejection fraction (HFpEF) (page 213, column 2) (do not teach contacting cardiac tissue with non-glycosylated FSTL1 or treating cardiometabolic heart disease) Zwijsen et al. Eur J Biochem 225: 937-946, 1994 (teach rat, mouse, and human FSTL1 sequences) Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIDGET E BUNNER whose telephone number is (571)272-0881. The examiner can normally be reached Monday-Friday 9:00 am-6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joanne Hama can be reached at (571) 272-2911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. BEB Art Unit 1647 23 September 2026 /BRIDGET E BUNNER/Primary Examiner, Art Unit 1647
Read full office action

Prosecution Timeline

Sep 23, 2024
Application Filed
Sep 28, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780910
ANTI-INFLAMMATORY PEPTIDES, PHARMACEUTICAL COMPOSITION CONTAINING SUCH PEPTIDES, AND USES THEREOF
4y 8m to grant Granted Nov 03, 2026
Patent 12780911
GLYCOSYLATED POLYPEPTIDES
4y 5m to grant Granted Nov 03, 2026
Patent 12741015
SUPPRESSION OF DIABETES USING EXOSOMES FROM STEM CELL PROGRAMMED MYELOID CELLS
4y 0m to grant Granted Sep 22, 2026
Patent 12735472
TNFR2 Agonists with Improved Stability
4y 9m to grant Granted Sep 15, 2026
Patent 12734214
Compositions and Methods for Increasing Epithelial Barrier Function
4y 5m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
84%
With Interview (+19.7%)
2y 10m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 846 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month